Brazil · Delayed Price · Currency is BRL Sarepta Therapeutics Company Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 835 |
| CEO | Douglas Ingram |
Contact Details
Address: 215 First Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 274 4000 |
| Website | sarepta.com |
Stock Details
| Ticker Symbol | S1RP34 |
| Exchange | Brazil Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Douglas S. Ingram Esq., J.D. | Chief Executive Officer and Director |
| Ian Michael Estepan | President and Chief Operating Officer |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research and Development and Technical Operations |
| Ryan H. Wong | Executive Vice President and Chief Financial Officer |
| Rachael Potter Ph.D. | Chief Scientific Officer |
| Tamara Thornton | Director of Finance, Treasury and Investor Relations |
| Cristin L. Rothfuss J.D. | Executive Vice President, General Counsel and Company Secretary |
| Alison Nasisi | Executive Vice President and Chief People Officer |
| Dr. Diane L. Berry Ph.D. | Executive Vice President and Chief of Global Policy and Advocacy Officer |
| Patrick Moss Pharm.D. | Executive Vice President and Chief Commercial Officer |